|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-10-2
|
|
pubmed:abstractText |
The growth factor receptors EGFR and HER-2/neu are targets for new treatment strategies and are of potential use as prognostic and predictive factors. However, the optimal method of determination in order to obtain clinically relevant information remains a source of controversy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0393-6155
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
131-40
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17013794-Adult,
pubmed-meshheading:17013794-Aged,
pubmed-meshheading:17013794-Aged, 80 and over,
pubmed-meshheading:17013794-Breast Neoplasms,
pubmed-meshheading:17013794-Humans,
pubmed-meshheading:17013794-Immunohistochemistry,
pubmed-meshheading:17013794-Middle Aged,
pubmed-meshheading:17013794-Neoplasm Metastasis,
pubmed-meshheading:17013794-Protein Structure, Tertiary,
pubmed-meshheading:17013794-Receptor, Epidermal Growth Factor,
pubmed-meshheading:17013794-Receptor, erbB-2,
pubmed-meshheading:17013794-Survival Analysis,
pubmed-meshheading:17013794-Tumor Markers, Biological
|
|
pubmed:articleTitle |
Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer.
|
|
pubmed:affiliation |
Department of Gynecology, University Medical Center Hamburg-Eppendorf, Germany.
|
|
pubmed:publicationType |
Journal Article
|
